Abstract:The synthesis of a range of 3-hydroxy-4(1H)-pyridinones with potential for the chelation of iron(III) is described. The pK(a) values of respective ligands and the stability constants of their iron(III) complexes are presented, The distribution coefficient values of a range of 48 hydroxypyridinones and their corresponding iron(III) complexes between l-octanol and MOPS buffer (pH 7.4) are reported. The range of log D-complex values covers 7 orders of magnitude. The results suggest the existence of a biphasic relationship between the distribution coefficient values of the chelator and the corresponding iron(III) complexes. For ligands with a log D-ligand = -1, a linear relationship exists with a value of the slope 2.53, whereas with ligands with a log D-ligand < -1, a linear relationship exists with a slope of 0.49. The reduced slope for the more hydrophilic molecules of the series offers some advantage for this type of hydroxypyridinone as the distribution coefficients for such complexes do not change so rapidly with increasing ligand hydrophilicity. The ability of selected 3-hydroxypyridinones to facilitate the excretion of iron in bile was investigated in non-iron-overloaded, bile duct-cannulated rats and in a [Fe-59]ferritin-loaded rat model. Both systems compare the ability of chelators to remove iron from the liver, the prime target organ in thalassemia. The N-(hydroxyalkyl)-3-hydroxypyridin-4-ones are demonstrated to be orally active under the in vivo conditions adopted. Thus both 1-(hydroxyalkyl)- and 1-(carboxyalkyl)pyridinones are able to remove iron from the liver. Although 1-(carboxyalkyl)hydroxypyridinones are active, they do not demonstrate any clear advantage over Deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one). Indeed 1-(hydroxyalkyl)hydroxypyridinones which are known to be rapidly converted to 1-(carboxyalkyl)hydroxypyridinones are also marginally superior to Deferiprone. In contrast, 2-ethyl-1-(2'-hydroxyethyl)-3-hyaroxypyridin-4-one, which is not metabolized to the corresponding (carboxyalkyl)hydroxypyridinone, was found to be superior to Deferiprone and therefore deserves further consideration as an orally active iron chelator with potential for the treatment of iron overload associated with transfusion-dependent thalassemia.

Novel Iron(iii) Complexes Based on 2-Hydrazinylpyrimidine Derivative: Synthesis, Characterization and Preliminary Evaluation of Antitumor Activity

Synthesis, cytotoxicity and DNA binding of novel Ni(II), Co(II) and Zn(II) complexes bearing pyrimidinyl hydrazone ligand

Synthesis and Investigations of the Antitumor Effects of First-Row Transition Metal(II) Complexes Supported by Two Fluorinated and Non-Fluorinated β-Diketonates

Synthesis, Physicochemical Properties, and Evaluation of<i>N</i>-Substituted-2-alkyl-3-hydroxy-4(1<i>H</i>)-pyridinones<sup>†</sup>

Four iron(II) carbonyl complexes containing both pyridyl and halide ligands: Their synthesis, characterization, stability, and anticancer activity

Novel tetranuclear grid-like Zn(II) complexes derived from dihydrazone pyrimidine derivatives as antitumor agents

Palladium(II) Complexes with N,N′-Dialkyl-1,10-phenanthroline-2,9-dimathanamine: Synthesis, Characterization and Cytotoxic Activity

Pyrimidine-based Iron(iii) Complexes of 2-(Pyrimidin-2-ylhydrazonomethyl)-phenol: Synthesis, Crystal Structure and Magnetic Properties

Manipulating Fe(II) spin states to achieve higher anti-tumor cell activities in multinuclear complexes

Synthesis, structure and anticancer studies of Cu (II), Ni (II) and Co (II) complexes based on 2,3-dihydroxybenzaldehyde-2-(2-aminophenyl)benzimidazole Schiff base

1,3,5-Triaza-7-phosphaadamantane and Cyclohexyl Groups Impart to Di-Iron(I) Complex Aqueous Solubility and Stability, and Prominent Anticancer Activity in Cellular and Animal Models

Three water-soluble acylhydrazone tetranuclear transition metal complexes: Crystal structures, DNA/BSA interactions and cytotoxicity studies

Design, synthesis, and biological evaluation of novel halogenated chlorido[N,N'-bis(salicylidene)-1,2-bis(3-methoxyphenyl)ethylenediamine]iron(III) complexes as anticancer agents

Evaluation of Efficiency of Liposome-Entrapped Iridium(III) Complexes Inhibiting Tumor Growth In Vitro and In Vivo

Pyridine hydrazyl thiazole metal complexes: Synthesis, crystal structure, antibacterial and antitumor activity

Synthesis, Structure and Characterization of Novel Nickel(ii) and Iron(ii) Complexes with a 5,5′-Bis[2-(2,2′-bipyridin-6-yl)-ethyl]-2,2′-bipyridine Ligand

New polyazamacrocyclic 3-hydroxy-4-pyridinone based ligands for iron depletion antitumor activity

Synthesis, structural studies, interaction with DNA/HSA and antitumor evaluation of new Cu(II) complexes containing 2-(1H-imidazol-2-yl)pyridine and amino acids

Syntheses, Characterization and Antitumor Activity of Three Mononuclear Ruthenium(II) Complexes

Half-sandwich Iridium N-heterocyclic Carbene Anticancer Complexes

Synthesis, characterization and cytotoxicity of lanthanum(III) complexes with novel 1,10-phenanthroline-2,9-bis-α-amino acid conjugates